Home › Funds › ARMISTICE CAPITAL, LLC › GSK
ARMISTICE CAPITAL, LLC position in GSK
GSK PLC · Health Care
ARMISTICE CAPITAL, LLC reported holding 724,000 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$34.9M, representing 0.48% of its reported portfolio and ranking #23 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed GSK holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ARMISTICE CAPITAL, LLC's GSK position evolved
ARMISTICE CAPITAL, LLC first disclosed a stake in GSK in Q3 2023 at 285,000 shares (US$10.3M). The position peaked in Q4 2023 at 2,196,000 shares, worth US$81.4M. Across 11 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 724,000 shares valued at US$34.9M — an increase of 424,000 shares quarter over quarter.. Notable position changes include a 671% increase in Q4 2023 (shares rose 16% over the following quarter), a 354% increase in Q4 2024 (shares rose 15% over the following quarter), a 141% increase in Q3 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 285.00K | $10.33M | New |
| Q4 2023 | 2.20M | $81.38M | Add |
| Q1 2024 | 964.00K | $41.33M | Reduce |
| Q2 2024 | 1.50M | $57.75M | Add |
| Q3 2024 | 524.00K | $21.42M | Reduce |
| Q4 2024 | 2.38M | $80.42M | Add |
| Q1 2025 | 378.00K | $14.64M | Reduce |
| Q4 2025 | 1.00M | $49.04M | New |
| Q1 2026 | 236.00K | $13.02M | Reduce |
| Q2 2026 | 300.00K | $15.73M | Add |
| Q3 2026 | 724.00K | $34.88M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.08B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 43.18M sh · $2.08B · Q3 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.19M sh · $1.21B · Q3 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.92M sh · $188.73M · Q3 2026
- EQUITY INVESTMENT CORP 3.56M sh · $171.52M · Q3 2026
More on ARMISTICE CAPITAL, LLC
FAQ
How long has ARMISTICE CAPITAL, LLC held GSK?
ARMISTICE CAPITAL, LLC has disclosed GSK holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is ARMISTICE CAPITAL, LLC's current position in GSK?
As of Q3 2026, ARMISTICE CAPITAL, LLC holds 724.00K shares of GSK (GSK PLC), valued at $34.88M, representing 0.48% of its reported portfolio and ranking #23.
Has ARMISTICE CAPITAL, LLC been buying or selling GSK?
In the latest 13F filing (Q3 2026), ARMISTICE CAPITAL, LLC increased its position in GSK. The position peaked in Q4 2023 at 2.20M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.